355 related articles for article (PubMed ID: 29151530)
1. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.
Kitamura H; Kubota Y; Yamaguchi K; Kamachi K; Nishioka A; Yokoo M; Shindo T; Ando T; Kojima K; Kimura S
Intern Med; 2018 Mar; 57(6):855-860. PubMed ID: 29151530
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
3. Management of Multiple Myeloma.
Kumar SK
J Natl Compr Canc Netw; 2018 May; 16(5S):624-627. PubMed ID: 29784741
[TBL] [Abstract][Full Text] [Related]
4. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
5. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
[TBL] [Abstract][Full Text] [Related]
6. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
[TBL] [Abstract][Full Text] [Related]
7. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
8. A Case of Multiple Myeloma in a 17-Year-Old Girl Treated with Autologous Hematopoietic Stem Cell Transplantation (ASCT).
Man HV; Dung PC
Am J Case Rep; 2019 Nov; 20():1623-1629. PubMed ID: 31685790
[TBL] [Abstract][Full Text] [Related]
9. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N; Dhakal B; Fraser R; Estrada-Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C; Lekakis L; Lazarus HM; Mian H; Murthy HS; Nathan S; Nishihori T; Parrondo R; Patel SS; Solh M; Strouse C; Vesole DH; Kumar S; Qazilbash MH; Shah N; D'Souza A; Sidana S
Cancer; 2023 Jul; 129(14):2179-2191. PubMed ID: 37021929
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
11. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
[TBL] [Abstract][Full Text] [Related]
13. [Rapidly progressive AL amyloidosis in a patient with relapsed multiple myeloma after achieving a complete response to tandem autologous PBSCT].
Yagi H; Ozaki S; Sekimoto E; Shibata H; Shigekiyo T; Satake N
Rinsho Ketsueki; 2013 Dec; 54(12):2171-6. PubMed ID: 24452148
[TBL] [Abstract][Full Text] [Related]
14. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation.
Kawamura S; Tamaki M; Nakamura Y; Kawamura M; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Okada Y; Akahoshi Y; Kusuda M; Kameda K; Tanihara A; Kimura SI; Nakasone H; Kako S; Kanda Y
Acta Haematol; 2022; 145(5):553-559. PubMed ID: 35605591
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
[TBL] [Abstract][Full Text] [Related]
17. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG
Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Cavo M; Pantani L; Pezzi A; Petrucci MT; Patriarca F; Di Raimondo F; Marzocchi G; Galli M; Montefusco V; Zamagni E; Gamberi B; Tacchetti P; Brioli A; Palumbo A; Sonneveld P
Leukemia; 2015 Dec; 29(12):2429-31. PubMed ID: 26442610
[No Abstract] [Full Text] [Related]
19. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
20. [Multiple myeloma with myelofibrosis at diagnosis and aggressive extramedullary relapse after autologous stem cell transplantation].
Kodama Y; Saburi M; Kawano K; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
Rinsho Ketsueki; 2024; 65(1):1-6. PubMed ID: 38311382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]